Cooley advised Cytek Biosciences on its $200 million initial public offering of 14,564,635 shares of common stock. Cytek Biosciences, whose securities now trade on the Nasdaq Global Select Market under the symbol CTKB, is a leading cell analysis solutions company. Partners Gordon Ho, Patrick Loofbourrow and John McKenna led the Cooley team.
